Archives of Internal Medicine Vol. 160, No. 21, Pages 3270-3277. Datum: 27 november 2000 URL: http://archinte.ama-assn.org (home page) http://archinte.ama-assn.org/issues/v160n21/rfull/ioi00252.html (tekst) http://archinte.ama-assn.org/issues/v160n21/fig_tab/ioi00252_ft.html (Figures, tables) Exercise Capacity in Chronic Fatigue Syndrome --------------------------------------------- Author Information / Pascale De Becker, PhD; Johan Roeykens, PT; Masha Reynders, PT; Neil McGregor, MD, PhD; Kenny De Meirleir, MD, PhD Background / Patients with chronic fatigue syndrome (CFS) suffer from various symptoms, including debilitating fatigue, muscle pain, and muscle weakness. Patients with CFS can experience marked functional impairment. In this study, we evaluated the exercise capacity in a large cohort of female patients with CFS. Methods / Patients with CFS and matched sedentary control subjects performed a maximal test with graded increase on a bicycle ergometer. Gas exchange ratio was continuously measured. In a second stage, we examined only those persons who achieved a maximal effort as defined by 2 end points: a respiratory quotient of at least 1.0 and an age-predicted target heart rate of at least 85%. Data were assessed using univariate and multivariate statistical methods. Results / The resting heart rate of the patient group was higher, but the maximal heart rate at exhaustion was lower, relative to the control subjects. The maximal workload and maximal oxygen uptake attained by the patients with CFS were almost half those achieved by the control subjects. Analyzing only those persons who performed a maximal exercise test, similar findings were observed. Conclusions / When compared with healthy sedentary women, female patients with CFS show a significantly decreased exercise capacity. This could affect their physical abilities to a moderate or severe extent. Reaching the age-predicted target heart rate seemed to be a limiting factor of the patients with CFS in achieving maximal effort, which could be due to autonomic disturbances. Arch Intern Med. 2000;160:3270-3277 IOI00252 ------------------------------------------------------------------------------ A DIAGNOSIS of chronic fatigue syndrome (CFS), as defined in 19941 by the Centers for Disease Control and Prevention (CDC), Atlanta, Ga, requires unexplained fatigue for more than 6 months not due to continuing exertion, not resolved by rest, and accompanied by 4 or more of the following 8 symptoms: sore throat, tender lymph nodes, memory and concentration problems, joint pain, headache of a new type, unrefreshing sleep, and postexertional malaise lasting more than 24 hours. Chronic fatigue syndrome is characterized as a new onset of fatigue, serious enough to reduce daily activities by more than 50% and in the absence of any other medically identifiable disorders.1, 2 Patients with CFS exhibit marked impairment and sometimes have greater degrees of functional disability than do patients with other diseases such as type 2 diabetes mellitus, congestive heart failure, hypertension, acute myocardial infarction, major depression, relapsing or remitting multiple sclerosis,3 and acute infectious mononucleosis.4 Various studies have evaluated the ability of patients with CFS to perform exercise, but conflicting results have been published.5-10 Some authors believe the aerobic capacity of patients with CFS lies within the low normal range,6, 8, 9 whereas others report a reduced aerobic capacity relative to normal subjects5, 10 and to patients with irritable bowel syndrome.7 Taking into account that the population with CFS is very heterogeneous, these different findings could be due to a selection bias, the low number of individuals studied, or both. The aerobic potential of an individual is determined by cardiac output and muscle oxidative capacity. Muscle contractility also plays a very important role.11 Previous studies have considered whether these factors limit the ability to complete physically active tasks in CFS.9, 12-17 Although patients report significant reductions in physical capabilities and postexertional symptom exacerbation,12, 17 findings from their tests of muscle strength, endurance, and function are normal.9, 12, 17-21 Histological and metabolic studies give mixed results. Several studies of patients with CFS have shown reductions in muscle oxidative capacity and metabolism,16, 22 atrophy of the fast twitch fibers,23-25 mitochondrial abnormalities,23, 24, 26 increased lactic acid production during exercise,13-15 and myopathic features on single fiber electromyogram.27 However, these abnormalities are not consistent, contributing to the consensus that CFS is a heterogeneous disorder and that differences in patient populations and muscles studied may account for discrepancies between studies.28 Some authors believe that central rather than peripheral factors are responsible for the reduced physical capacity and the difficulty in performing a maximal effort.9, 11, 17, 29 Patients with CFS have exhibited repetitively negative changing T waves at Holter registrations30 and a slow acceleration of heart rate during exercise.10 It is suggested that the fatigue in CFS may be related to subtle cardiac dysfunction occurring at workloads common to ordinary living.30 The pathophysiology of exercise has been studied extensively in relation to cardiovascular, pulmonary, endocrine, and neuromuscular diseases, but little information exists on the interrelationship between physical exercise parameters and CFS.31 As there is only scant information on the physical capacity of patients with CFS, physicians who are called on to assist in the determination of the physiological capacity of these patients have no standards to rely on. The few studies that have been done involve limited numbers of patients, which could bias the results considering the heterogeneity of the CFS population. Therefore, we judged it necessary to study a large group of patients to be able to draw conclusions on their exercise capacity and degree of impairment. The standard for measuring exercise capacity has always been the maximal oxygen uptake ( Vdot O2max) during high intensity whole body exercise.11, 32 It is generally accepted that cardiopulmonary exercise testing is a good research tool for this purpose33 and is commonly used to determine an individual's exercise potential.34 We designed a maximal bicycle ergometric test against a graded increase in workload, which aimed to collect data regarding exercise capacity in a large cohort of female patients with CFS. These results were compared with a population of sedentary control female subjects and with findings reported in the literature on other sedentary healthy populations. METHODS PATIENTS AND CONTROL SUBJECTS A total of 450 consecutive female patients who met the CDC's 1988 or 1994 criteria for CFS were enrolled in the study, which had been approved by an ethical committee. Of these, 427 met the requirements and agreed to participate. The diagnosis of CFS was made by patient history, routine physical examination, and laboratory test results to exclude other relevant diagnoses, as recommended by Fukuda et al.1 A group of 204 age-matched sedentary women served as a control population. We selected them from subjects who came for medical checkups. Only those who did sitting work and performed a maximum of 1 hour of sports per week were included. Control subjects were accepted into the study only if they denied having symptoms of chronic fatigue and did not suffer from any medical conditions known to cause chronic fatigue. STUDY DESIGN All patients and controls underwent a bicycle ergometric test against a graded increase in workload until exhaustion. The exercise tests were performed at room temperature (20C-22C) and at a humidity of 40% to 60%. The subjects assumed the sitting position on the electromagnetically braked ergometer (Jaeger 900; Lode B.V., Groningen, the Netherlands), and the test was started after 3 to 5 minutes of adjustment. Heart rate was continuously monitored at rest and during exercise. There was continuous recording of the 12-lead electrocardiogram using an electrocardiograph (Marquette Electronics Inc, Milwaukee, Wis). An open circuit spirometer (Mijnhart Oxycon; IBM, Bunnik, the Netherlands) with automatic printout every 30 seconds was used to collect pulmonary data during the test. As such, data for Vdot O2max and maximal carbon dioxide production were averaged for every 30-second interval during each stage. Expired air was collected via a 2-way breathing valve attached to a mask that covered the subject's nose and mouth and was analyzed continuously for ventilatory and metabolic variables. Before each test, the spirometer was calibrated for ambient conditions. The increments were chosen to obtain a total exercise duration between 8 and 12 minutes, which is suggested as an optimal test period.34 Thus, the duration of exercise was kept below 15 minutes to avoid possible early onset fatigue in the lower limbs because of lack of physical fitness. The patients with CFS started at 10 W, with an increase of 10 W/min. The control population began at 40 W, with an increase of 30 W every 3 minutes. The following parameters were measured: heart rate at rest (HRrest), maximal heart rate (HRmax), maximal work capacity attained, Vdot O2max per kilogram of body weight, maximal respiratory quotient (RQmax), heart rate at RQ of 1.0 (HRAT), peak work rate at RQ of 1.0 (WAT), and the percentage of target heart rate (THR) that was achieved. The metabolic data analyzed were the means of the last 30 seconds from the final stage of exercise or the highest value attained if a decline in Vdot O2 occurred at the final workload. A separate analysis between patients and controls was done with all those who performed a maximal exercise test. The criteria used for determining whether the subject had attained a physiological maximum were the accomplishment of 2 end points: (1) an RQ greater than 1.0 and (2) reaching at least 85% of the age-predicted THR. The HRmax achievable during exercise of large muscles (eg, with use of a bicycle ergometer) is generally equivalent to 220 minus the subject's age in years, plus or minus 20 beats per minute.35 Data were sent to Neil McGregor, MD, PhD, at the University of Newcastle, Australia, for independent analysis to reduce any possibility of bias. STATISTICAL ANALYSIS Data distributions were evaluated for violations of assumptions with parametric statistical analyses. The percentage of THR was arcsine transformed, while all other exercise response variables were log transformed to improve normality and linearity. Subject characteristics were assessed using chi 2 probability and t tests. Univariate group differences were evaluated on untransformed data using the nonparametric Mann-Whitney test. Multivariate group differences were determined on transformed data using standard and forward stepwise discriminant function analyses. Pearson product moment correlation was used to investigate within-group differences in the associations between variables. These data were processed using statistical software (Access97 and Excel97; Microsoft, Redmond, Wash, and Statistica, version 5.1; Statsoft, Tulsa, Okla). RESULTS There was no difference in age between the patients with CFS and the control subjects (mean + SD years, 37.0 + 9.0 and 35.9 + 9.2, respectively). All individuals in the study were white Europeans. Those with CFS had a mean illness duration of 7.0 + 6.4 years. Discriminant function analysis was applied to determine the major characteristics that differentiated between the exercise response profiles of the CFS vs the control subjects. Table 1 shows that the regression model revealed a large deviation in the response characteristics between them (Wilks lambda = 0.14, F = 199.4; P<.001), with a high degree of homogeneity within the 2 groups. Most (97.8%) of the control subjects complied with the control model profile, and 99.7% of individuals with CFS complied with the CFS group profile. Univariate analysis showed that 10 of the 15 exercise profile measures were reduced in those with CFS compared with the control subjects and 1 parameter (HRrest) was increased. Table 1. Summary of the Univariate and Multivariate Analyses of the Differences Between CFS and Control Female Subjects^* --------------------------------------------------------------------------- Parameter CFS Control Univariate P Multivariate P --------------------------------------------------------------------------- Heart rate at AT, bpm 135.4 (1.1) 149.9 (1.3) <.001 <.001 Workload at AT, W 72.8 (1.5) 123.0 (2.7) <.001 <.001 Workload per body 1.51 (0.03) 2.7 (0.1) <.001 <.001 weight, W/ kg Exercise duration, min 9.1 (0.2) 10 (0.2) <.002 <.001 VO_2max. L/min 1.23 (0.02) 1.93 (0.03) <.001 <.001 Maximum workload, W 90.5 (1.6) 162.9 (2.7) <.001 <.001 Weight, kg 60.8 (0.63) 60.3 (0.5) .65 <.001 % Target heart rate 82.5 (0.6) 92.6 (0.6) <.001 <.001 VO_2max/body weight. 20.5 (0.3) 32.0 (0.6) <.001 .29 mL/kg per minute Maximum respiratory 1.11 (0.01) 1.19 (0.01) <.001 .29 quotient Maximum heart rate, 151.3 (1.2) 170.7 (1.2) <.001 .42 bpm Resting heart rate, 88.8 (0.8) 81.9 (0.8) <.001 .73 bpm Body surface area, m^2 1.65 (0.01) 1.66 (0.01) .68 .66 Target heart rate, 183.0 (0.5) 184.1 (0.7) .20 .30 bpm Height, cm 164.6 (0.4) 165.5 (0.4) .13 .21 --------------------------------------------------------------------------- * Data are given as mean (SE). CFS indicates chronic fatigue syndrome; AT, anaerobic threshold; bpm, beats per minute; and VO_2max=, maximal oxygen uptake. Univariate statistical analysis was by Mann-Whitney test; multivariate, standard discriminant function (a<0.05). Forward stepwise discriminant function analysis was used to assess the major parameters that determined the different response characteristic profiles in the CFS vs the control groups. A strong model was found (Wilks lambda = 0.136, F = 301.3), with HRAT being the primary discriminating variable, followed by WAT and the maximal workload per kilogram of body weight (P<.001 for all). Thus, the exercise response characteristics of the CFS and the control subjects were very dissimilar, principally in HRAT and WAT. Pearson product moment correlation analysis was undertaken to assess any differences in the exercise parameters between the 2 groups to allow a better understanding of how exercise capacity varied. Table 2 summarizes the correlation comparisons between WAT and HRAT with the heart rate parameters and RQ in the patients with CFS vs the control subjects. There was a significant disregulation of the relationships between WAT and HRAT with disregulation of the heart rate parameters. Therefore, variation in heart rate was strongly related to changes in exercise capacity in the patients with CFS. Table 2. Pearson Product Moment Correlation Differences With the Primary Discriminant Parameters and Heart Rate Parameters and Respiratory Quotient in the CFS and Control Female Subjects^* --------------------------------------------------------------------------- Parameter Workload at Anaerobic Threshold Heart Rate at Anaerobic Threshold CFS Control P for CFS Control P for Difference Difference --------------------------------------------------------------------------- Maximum 0.37 (<.001) 0.70 (<.001) <.001 0.74 (<.001) 0.22 (<.003) <.001 heart rate % Target 0.33 (<.001) 0.51 (<.003) <.02 0.64 (<.001) 0.11 (.14) <.001 heart rate Target 0.12 (.04) 0.14 (.05) .83 0.28 (<.001) 0.08 (.54) <.03 heart rate Resting ~0.07 (.63) 0.38 (<.001) <.001 0.54 (<.001) ~0.12 (.12) <0.001 heart rate,. Maximum ~0.17 (<.003) ~0.11 (.14) .51 ~0.11 (.06) ~0.25 (<.001) .12 respiratory quotient --------------------------------------------------------------------------- * CFS indicates chronic fatigue syndrome. Data are given as difference (P). Figure 1 shows the comparative scatterplot of WATand HRAT in the 2 groups. While there was a similar correlation between WAT and HRAT (CFS, r = 0.50; control, r = 0.56; P<.001 for both), there was a large reduction in both parameters in the patients with CFS (Table 1). Figure 2, Figure 3, and Figure 4 illustrate the association between HRAT and WAT, Vdot O2max, and exercise duration in the patients with CFS and in control subjects. These figures demonstrate that the relationships between these 3 factors were quite different in the 2 groups. Figure 1. -------------------------------------------------- Categorized scatterplot of the differences in workload and heart rate at the anaerobic threshold in patients with chronic fatigue syndrome (CFS) and in control female subjects. The diagonal solid line represents 95% confidence interval (regression analysis); diagonal dashed lines, 95% confidence limits (1 SD). -------------------------------------------------- Figure 2. -------------------------------------------------- Categorized scatterplot of the differences in maximum workload and heart rate at the anaerobic threshold in chronic fatigue syndrome (CFS) and in control female subjects. The diagonal solid line represents 95% confidence interval (regression analysis); diagonal dashed lines, 95% confidence limits (1 SD). -------------------------------------------------- Figure 3. -------------------------------------------------- Categorized scatterplot of the differences in O2max and heart rate at the anaerobic threshold in chronic fatigue syndrome (CFS) and in control female subjects. The diagonal solid line represents 95% confidence interval (regression analysis); diagonal dashed lines, 95% confidence limits (1 SD). -------------------------------------------------- Figure 4. -------------------------------------------------- Categorized scatterplot of the differences in exercise duration and heart rate at the anaerobic threshold in chronic fatigue syndrome (CFS) and in control female subjects. The diagonal solid line represents 95% confidence interval (regression analysis); diagonal dashed lines, 95% confidence limits (1 SD). -------------------------------------------------- The maximal respiratory quotient was positively correlated with exercise duration, HRmax, and the percentage of THR in both groups (all r >0.25; P<.001). In the patients with CFS, RQmax was positively associated with WAT(r = 0.26; P<.001) and negatively associated with HRAT (r = -0.15; P<.01). In the control individuals, RQmax was positively correlated with HRrest (r = 0.17; P<.02) and negatively correlated with WAT(r = -0.24; P<.002). The percentage of THR was positively associated with exercise duration, HRrest and HRmax, maximum workload, Vdot O2max, HRATand WAT, and RQmax in both groups (all r >0.25; P<.001). In the control subjects, the percentage of THR was negatively correlated with the THR (r = -0.16; P<.04). In those with CFS, the percentage of THR had a statistically higher correlation coefficient for WAT (CFS = 0.63, control = 0.15; P<.001, for difference) and maximum workload (CFS = 0.53, control = 0.28; P<.002, for difference) and a statistically lower correlation coefficient for HRAT (CFS = 0.31, control = 0.52; P<.007, for difference). Thus, in patients with CFS, the reduction in the percentage of THR achieved was associated with a reduction in workload capacity. Those with CFS had a higher HRrest and a lower HRmax relative to the control subjects (Table 1), and therefore the increase from resting to maximum heart rate was calculated for the sake of comparison. It was lower in the patients with CFS vs the control subjects (CFS = 62.5 + 19.0 beats per minute, control = 88.9 + 14.4 beats per minute; P<.001). In the CFS group, the increase in heart rate from rest to maximum had a higher positive correlation with the maximum workload (CFS = 0.68; control = 0.45) and exercise duration (CFS = 0.68; control = 0.47) (P<.001 for all) compared with the control subjects. In the second stage of the study, we examined only those persons who attained a maximal effort as defined by 2 end points: achievement of an RQ of at least 1.0 and an age-predicted THR of at least 85%. A relatively small percentage of patients with CFS, 37%, reached both criteria (Table 3). The target heart rate seemed to be the limiting factor, since only 41% of the patients achieved an HRmax of at least 85% of the age-predicted THR, whereas 80% of them reached the anaerobic threshold defined by a minimal RQ of 1.0. Thus, for comparison, we analyzed the metabolic data of those subjects who had achieved a maximal effort in both study groups (Table 4). Table 3. Prevalence of CFS and Control Female Subjects Who Attained the Maximal Exercise Parameters^* --------------------------------------------------------------------------- Group CFS Control All subjects 427 (100) 204 (100) THR >85% 174 (41) 174 (85) RQ >1.0 342 (80) 192 (94) THR >85% and RQ>1.0 157 (37) 163 (80) --------------------------------------------------------------------------- * Data are given as number (percentage). CFS indicates chronic fatigue syndrome; THR, target heart rate; and RQ, respiratory quotient. Table 4. Summary of the Univariate and Multivariate Analyses of the Differences Between CFS and Control Female Subjects Who Achieved Both Parameters Defining a Maximal Effort^* --------------------------------------------------------------------------- Parameter CFS Control Univariate P Multivariate P --------------------------------------------------------------------------- Heart rate at AT, bpm 80.9 (2.2) 153.1 (1.3) <.001 <.001 Workload at AT, W 145.8 (1.4) 125.3 (2.9) <.001 <.001 Exercise duration, min 10.4 (0.2) 10.4 (0.3) .63 <.001 Workload per body 1.75 (0.04) 2.84 (0.5) <.001 <.001 weight, W/ kg Maximum workload, W 104.3 (2.2) 168.7 (2.8) <.001 <.001 Weight, kg 60.8 (0.8) 59.9 (0.5) .90 <.001 VO_2max. L/min 1.36 (0.02) 1.99 (0.03) <.001 <.001 % Target heart rate 91.5 (0.4) 95.0 (0.4) <.001 <.04 Target heart rate, 183.8 (0.8) 183.8 (0.9) .51 <.03 bpm Maximum respiratory 1.13 (0.01) 1.20 (0.01) <.001 <.04 quotient VO_2max/body weight. 22.7 (0.4) 32.9 (0.6) <.001 .83 mL/kg per minute Resting heart rate, 93.0 (1.2) 83.5 (0.9) <.001 .71 bpm Maximum heart rate, 167.4 (1.0) 175.4 (0.8) <.001 .15 bpm Body surface area, m^2 1.66 (0.01) 1.65 (0.01) .77 .26 Height, cm 165.2 (0.5) 165.6 (0.4) .55 .83 --------------------------------------------------------------------------- * Data are given as mean (SE). CFS indicates chronic fatigue syndrome; AT, anaerobic threshold; bpm, beats per minute; and VO_2max=, maximal oxygen uptake. Univariate statistical analysis was by Mann-Whitney test; multivariate, standard discriminant function (a<0.05). There was no difference in age between the 141 patients with CFS and the 158 control subjects (mean + SD years, CFS = 36.2 + 9.4; control = 35.5 + 9.0) who achieved maximal effort. Those with CFS had a mean illness duration of 6.8 + 7.0 years. Discriminant function analysis was applied to determine the major differences between the exercise response characteristics of the patients with CFS vs the control subjects who achieved maximal effort. Table 4 shows that the regression model revealed a large difference in these characteristics (Wilks lambda = 0.10, F = 158.8; P<.001), with a high degree of homogeneity within the 2 groups. All of the control subjects complied with the control model profile, and 99.3% of the patients with CFS complied with the CFS group profile. Univariate analysis demonstrated that 8 of the 15 exercise profile measures were reduced in the CFS group relative to the control group and 2 were increased (HRrest and WAT). Compared with the initial analysis in the entire study group, the patients with CFS who achieved maximal responses showed no difference in exercise duration. Most of the exercise parameters found to be dissimilar between the CFS and control groups were the same in patients who achieved maximal responses relative to those in the entire cohort of patients with CFS. Therefore, the exercise capacity in the patients with CFS who reached their maximal response was still quite different from that of the control subjects. Forward stepwise discriminant function analysis was applied to evaluate the major parameters that determined the differences between the exercise response characteristic profiles of the CFS vs the control groups who achieved maximal effort. A strong model was found (Wilks lambda = 0.11, F = 184.3), with HRAT being the primary discriminating variable, followed by WAT and maximal workload per kilogram of body weight (P<.001 for all). These data show that the parameters differentiating the 2 groups were the same when analyzing only those in the cohort who achieved maximal exercise responses. COMMENT Exercise capacity was evaluated in a large cohort of female patients with CFS and compared with that of sedentary control subjects. The O2max levels of our control group were consistent with various studies in untrained women of approximately the same age describing Vdot O2max levels of 30 to 36 mL/kg per minute).31, 32 Our patients with CFS had an average Vdot O2max just below 20 mL/kg per minute, representing significant impairment relative to the controls. Comparing the exercise capacity in our patients with data from other studies shows a functionality similar to that of elderly healthy controls (60-69 years),31 individuals with chronic heart failure,36 patients with chronic obstructive or restrictive pulmonary disease,37 and those with skeletal muscle disorder.38 The decrease in physical capacity in patients with CFS appears to be associated with disease severity and is consistent with the reduction seen in many other chronic illnesses. A major criterion for defining CFS is that patients report a greater than 50% reduction in activity levels relative to their pre-illness state.2 Maximal workload at exhaustion averaged 53% of normal in our patients with CFS, which is close to the 50% decrease in physical capabilities described in the CDC's criteria for CFS.1, 2 Sisto6 and Riley7 and their colleagues reported only slight reductions in aerobic power on a graded treadmill test in female patients with CFS. Their patients had an average Vdot O2max of 30.1 mL/kg per minute and 31.7 mL/kg per minute, respectively, which places them within the range of sedentary control subjects according to the classification by MacAuley et al.32 We believe that the failure to assess the more severely affected patients appears to have led to a disparity in study conclusions about the exercise capacity in patients with CFS. In contrast to many investigators5-8 who have claimed heterogeneity of laboratory and exercise findings when comparing their results with other CFS studies, our study shows a high degree of homogeneity within the CFS group in multivariate analysis. Our statistical homogeneity is an assessment of the differences between the 2 groups evaluated and does not necessarily reflect clinical homogeneity. The contradictions between our study and the heterogeneous findings in other studies may also result from the array of measures used, different study designs and numbers, and various interpretations given to the results of those investigations. Only a small number of patients with CFS reached both parameters for maximal exercise testing (RQ >1.0 and HRmax >85% THR). However, when we analyzed the entire cohort data using only those subjects who fulfilled the criteria for maximal exercise, we still observed the same differences in exercise capacity between the CFS group and the control subjects. Multiple regression analysis showed that the same parameters differentiated between the CFS and control groups as in the cohort. The resting heart rate was higher in patients with CFS, as in other studies.5, 7 Moreover, most of our patients were not able to achieve their age-predicted THR, a finding that is in agreement with some previous studies in CFS.8, 10, 17, 20 Although some authors5, 8 believe that the inability to reach the THR indicates incapability to exercise to full capacity, because of elevated perceptions of exertion or fatigue or physical deconditioning, a large percentage of our patients who did not reach their age-predicted THR did reach their RQ of 1.0. Furthermore, Gibson et al17 observed similar heart rates at increasing workloads in CFS and control subjects, which is more consistent with submaximal exertion than with deconditioning.5 The increase in HRrest associated with a lower achieved HRmax suggests that alteration in cardiac function is a primary factor associated with the reduction in exercise capacity in CFS. It is a peculiar finding that, although most of our patients reached the respiratory anaerobic threshold, far fewer of them also reached their THR. This would also indicate that suboptimal cardiac function is a major limiting factor in exercise capacity in patients with CFS. Fischler et al5 use only the THR criteria to assess whether a patient did or did not perform a maximal effort. This would suggest that too great an emphasis is placed on the THR, especially since several studies39-43 suggest autonomic nervous system involvement in CFS that could influence the chronotropic cardiac systems. It could be that the increased HRrest and the low HRmax are the result of a disturbed autonomic system. Possible disturbances include sympathetic predominance,37, 42 diminished vagal power,41 and reduced sympathetic responsiveness to stress42 and exercise.44 Considering that 66% to 90% of patients with CFS initially develop an acute infectious illness,45 exercise bradycardia might also be related to post-acute viral status, either as a direct or indirect latent effect, and the possibility that cellular metabolic pathways are disrupted by the viral presence or by some immunological process triggered by the acute or persistent infection.46 The exact mechanisms for this are speculative. It may be that loss of muscle protein contributes to the perceived muscle weakness.47 Cytokine abnormalities and dysfunction of the 2-5A Synthetase/RNaseL pathway exert a negative control on protein synthesis. Both of these anomalies have been demonstrated in CFS.48-50 In addition, muscle fiber atrophy23-25 and a defect in muscle energy sources need to be explored as there is disagreement whether patients with CFS show defects in mitochondrial function.14, 23, 24, 26 This study clearly shows that patients with CFS are limited in their physical capacities. Based on the American Medical Association Guidelines for Impairment Rating,51 our 55.2% of patients who had a Vdot O2max of less than 20 mL/kg per minute correspond to class 3-4 on the disability scale, indicating moderate to severe impairment.51 Regardless of the cause and pathogenesis, the symptom complex labeled CFS can and does result in prolonged debilitation.3, 4, 51 To our knowledge, this is the first study on exercise capacity in a large population of patients with CFS and sedentary control subjects. Physical capacity based on exercise tolerance is only one of a number of factors that might be considered in establishing a more global impairment rating. However, we believe it is a strong and useful tool in assessing a person's physical capability. Author/Article Information From the Human Performance Laboratory and Department of Internal Medicine, Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel, Brussels, Belgium (Drs De Becker and De Meirleir, Mr Roeykens, and Ms Reynders); and the Collaborative Pain Research Unit, Department of Biological Sciences, Faculty of Science, University of Newcastle, Callaghan, New South Wales, Australia (Dr McGregor). Corresponding author: Pascale De Becker, PhD, Human Performance Laboratory and Department of Internal Medicine, Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel, LK - Third Floor, Pleinlaan 2, 1050 Brussels, Belgium (e-mail: pdbeck@minf.vub.ac.be). Accepted for publication June 7, 2000. REFERENCES 1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953-959. 2. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988;108:387-389. 3. Komaroff AL, Fagioli LR, Doolittle TH, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med. 1996;101:281-290. 4. Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. Am J Med. 1996;171:364-370. 5. Fischler B, Dendale P, Michiels V, Cluydts R, Kaufmann L, De Meirleir K. Physical fatigability and exercise capacity in the chronic fatigue syndrome: association with disability, somatisation, and psychopathology. J Psychosom Res. 1997;42:369-378. 6. Sisto SA, Lamanca J, Cordero DL, et al. Metabolic and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome. Am J Med. 1996;100:634-640. 7. Riley MS, O'Brien CJ, McCluskey DR, Bell NP, Nicholls DP. Aerobic work capacity in patients with chronic fatigue syndrome. BMJ. 1990;301:953-956. 8. Rowbottom D, Keast D, Pervan Z, Morton A. The physiological response to exercise in chronic fatigue syndrome. J Chronic Fatigue Syndrome. 1998;4:33-49. 9. Kent-Braun JA, Sarma KR, Weiner MW, Massie B, Miller RG. Central basis of muscle fatigue in chronic fatigue syndrome. Neurology. 1993;43:125-131. 10. Montague TJ, Marrie TJ, Klassen GA, Bewick DJ, Horacek BM. Cardiac function at rest and with exercise in the chronic fatigue syndrome. Chest. 1989;95:779-784. 11. Noakes TD. Implications of exercise testing for prediction of athletic performance: a contemporary perspective. Med Sci Sports Exerc. 1988;20:319-330 12. McCully KK, Sisto SA, Natelson BH. Use of exercise for treatment of chronic fatigue syndrome. Sports Med. 1996;21:35-48. 13. Arnold DL, Bore PJ, Radda GK, Styles P, Taylor DJ. Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. Lancet. 1984;1:1367-1369. 14. Barnes PR, Taylor DJ, Kemp GJ, Radda GK. Skeletal muscle bioenergetics in the chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 1993;56:679-683. 15. Lane RJ, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard LC. Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 1998;64:362-367. 16. Wong R, Lopaschuk G, Zhu G, et al. Skeletal muscle metabolism in the chronic fatigue syndrome: in vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest. 1992;102:1716-1722. 17. Gibson H, Carroll N, Clague JE, Edwards RH. Exercise performance and fatiguability in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 1993;56:993-998. 18. Lloyd AR, Gandevia SC, Hales JP. Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome. Brain. 1991;114:85-98. 19. Lloyd AR, Hales JP, Gandevia SC. Muscle strength, endurance and recovery in the post-infection fatigue syndrome. J Neurol Neurosurg Psychiatry. 1988;51:1316-1322. 20. Stokes MJ, Cooper RG, Edwards RH. Normal muscle strength and fatigability in patients with effort syndromes. BMJ. 1988;297:1014-1017. 21. Rutherford OM, White PD. Human quadriceps strength and fatiguability in patients with post viral fatigue. J Neurol Neurosurg Psychiatry. 1991;54:961-964. 22. McCully KK, Natelson BH, Iotto S, Sisto S, Leigh JS. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve. 1996;19:621-625. 23. Behan WM, More IA, Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol (Berl). 1991;83:61-65. 24. Byrne E, Trounce I. Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle. J Neurol Neurosurg Psychiatry. 1987;50:743-746. 25. Gow JW, Behan WM, Simpson K, et al. Studies on enterovirus in patients with chronic fatigue syndrome. Clin Infect Dis. 1994;18(suppl 1):S126-S129. 26. Behan WMH, Holt IJ, Kay DH, Moonie P. In vitro study of muscle aerobic metabolism in chronic fatigue syndrome. J Chronic Fatigue Syndrome. 1999;5:3-15. 27. Jamal GA, Hansen S. Post-viral fatigue syndrome: evidence for underlying organic disturbance in the muscle fibre. Eur Neurol. 1989;29:273-276. 28. Lodi R, Taylor DJ, Radda GK. Chronic fatigue syndrome and skeletal muscle mitochondrial function. Muscle Nerve. 1997;20:765-766. 29. Edwards RH, Gibson H, Clague JE, Helliwell T. Muscle physiology and histopathology in chronic fatigue syndrome. In: Bock GR, Whelan J, eds. Chronic Fatigue Syndrome. Chichester, England: John Wiley & Sons Ltd; 1993:102-131. 30. Lerner AM, Lawrie C, Dworkin HS. Repetitively negative changing T waves at 24-h electrocardiographic monitors in patients with the chronic fatigue syndrome. Chest. 1993;104:1417-1421. 31. Lewis SF, Haller RG. Physiologic measurement of exercise and fatigue with special reference to chronic fatigue syndrome. Rev Infect Dis. 1991;13(suppl 1):S98-S108. 32. MacAuley D, McCrum EE, Stott G, et al. Levels of physical activity, physical fitness and their relationship in the Northern Ireland Health and Activity Survey. Int J Sports Med. 1998;19:503-511. 33. Hollmann W, Prinz JP. Ergospirometry and its history. Sports Med. 1997;23:93-105. 34. Davis JA. Direct determination of aerobic power. In: Maud PJ, Foster C, eds. Physiological Assessment of Human Fitness. Champaign, Ill: Human Kinetics; 1995:9-17. 35. Astrand PO, Rodahl K. Evaluation of physical performance on the basis of tests. In: Astrand PO, Rodahl K, eds. Textbook of Work Physiology: Physiological Bases of Exercise. 3rd ed. New York, NY: McGraw-Hill; 1986:354-387. 36. Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation. 1984;69:1079-1087. 37. Wehr KL, Johnson RL Jr. Maximal oxygen consumption in patients with lung disease. J Clin Invest. 1976;58:880-890. 38. Lewis SF, Haller RG. Skeletal muscle disorders and associated factors that limit exercise performance. Exerc Sport Sci Rev. 1989;17:67-113. 39. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA. 1995;274:961-967. 40. De Becker P, Dendale P, De Meirleir K, Campine I, Vandenborne K, Hagers Y. Autonomic testing in patients with chronic fatigue syndrome. Am J Med. 1998;105(3A):22S-26S. 41. Sisto SA, Tapp W, Drastal S, et al. Vagal tone is reduced during paced breathing in patients with the chronic fatigue syndrome. Clin Auton Res. 1995;5:139-143. 42. Pagani M, Lucini D, Mela GS, Langewitz W, Malliani A. Sympathetic overactivity in subjects complaining of unexplained fatigue. Clin Sci (Colch). 1994;87:655-661. 43. Freeman R, Komaroff AL. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med. 1997;102:357-364. 44. Cordero DL, Sisto SA, Tapp WN, et al. Decreased vagal power during treadmill walking in patients with chronic fatigue syndrome. Clin Auton Res. 1996;6:329-333. 45. Schluederberg A, Straus SE, Peterson P, et al. Chronic fatigue syndrome research: definition and medical outcome assessment. Ann Intern Med. 1992;117:325-331. 46. Montague T, Marrie T, Klassen G, et al. Cardiac effects of common viral illnesses. Chest. 1988;94:919-925. 47. Preedy VR, Smith DG, Salisbury JR, Peters TJ. Biochemical and muscle studies in patients with acute post-viral fatigue syndrome. J Clin Pathol. 1993;46:722-726. 48. Lloyd A, Hickie I, Brockman A, Dwyer J, Wakefield D. Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects. J Infect Dis. 1991;164:1023-1024. 49. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A Synthetase/RNaseL antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis. 1994;18(suppl 1):S96-S104. 50. Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel low molecular weight RNaseL in chronic fatigue syndrome. J Interferon Cytokine Res. 1997;17:377-385. 51. Make B, Jones JF. Impairment of patients with chronic fatigue syndrome. J Chronic Fatigue Syndrome. 1997;3:43-55. -------- (c) 2000 American Medical Association